Recent News
Our Product
Our first approved product is indicated for the acute treatment of migraine with or without aura in adults.
Our Focus
SMART Platform
Satsuma’s SMART (Simple MucoAdhesive Release Technology) Platform is a transformative solution designed to overcome the inherent efficacy and administration limitations of current treatment formulations.
Publications
Our Research
Scientific publications from Satsuma regarding the use of DHE in the acute treatment of migraine.
Press Releases
Nov 26, 2024
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
Oct 31, 2024